Scholarlink

<p>Pathogenic variants in <i>BRCA1</i> and <i>BRCA2</i> account for the majority of hereditary breast and ovarian cancer (HBOC) cases, and are associated with substantial morbidity, mortality, and economic burden. Population screening for <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants (PVs) may enable cancer prevention and reduce downstream costs and mortality. The feasibility pilot of <i>BRCA1</i> and <i>BRCA2</i> PV population screening in Latvia was conducted among cancer-free females aged 25–59 years, using digital recruitment tools and saliva-based <i>BRCA1</i> and <i>BRCA2</i> gene NGS with CNV analysis. Psychological impact was assessed using PHQ-9 and GAD-7. After 3,438 email invitations and media campaigns, 536 participants provided samples. Eight PVs were identified, and all carriers reported at least one affected first-degree relative. PHQ-9 and GAD-7 scores showed no significant pre– and post-testing differences. Saliva-based population screening for <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants is feasible in Latvia showing considerable (1.5%) frequency of PVs, acceptable psychological outcomes, but requires improved engagement strategies and equitable access pathways.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

BRCA1 and BRCA2 population screening in Latvia: feasibility, engagement, and early lessons from a pilot study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • Arvids Irmejs,
  • Zanda Daneberga,
  • Kristine Kiploka,
  • Marta Augucevica,
  • Anneta Cerneikina,
  • Linda Gailite,
  • Agate Kalcenaua,
  • Ilva Kononova,
  • Emil Syundyukov,
  • Edvins Miklasevics,
  • Cathrine Bjorvatn,
  • Hildegunn Høberg Vetti,
  • Janis Gardovskis

摘要

Pathogenic variants in BRCA1 and BRCA2 account for the majority of hereditary breast and ovarian cancer (HBOC) cases, and are associated with substantial morbidity, mortality, and economic burden. Population screening for BRCA1 and BRCA2 pathogenic variants (PVs) may enable cancer prevention and reduce downstream costs and mortality. The feasibility pilot of BRCA1 and BRCA2 PV population screening in Latvia was conducted among cancer-free females aged 25–59 years, using digital recruitment tools and saliva-based BRCA1 and BRCA2 gene NGS with CNV analysis. Psychological impact was assessed using PHQ-9 and GAD-7. After 3,438 email invitations and media campaigns, 536 participants provided samples. Eight PVs were identified, and all carriers reported at least one affected first-degree relative. PHQ-9 and GAD-7 scores showed no significant pre– and post-testing differences. Saliva-based population screening for BRCA1 and BRCA2 pathogenic variants is feasible in Latvia showing considerable (1.5%) frequency of PVs, acceptable psychological outcomes, but requires improved engagement strategies and equitable access pathways.